IP Library Granted Patent US 10,624,868
Granted Patent B2
US 10,624,868 · App. 16/452,239 · Granted Apr 21, 2020

Bolus dose of hydroxycitric acid with glycerol

Inventors: Dallas L. Clouatre (Seattle, WA); Daniel E. Clouatre (Seattle, WA); Brad J. Douglass (Seattle, WA)
Assignee: GLYKON TECHNOLOGIES GROUP, LLC
A61K31/194A61J1/1412A61K9/0053A61K9/0095A61K9/14A61K9/145A61K31/00A61K31/047A61K31/216A61K36/185A61K36/42A61K36/74A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,868
App. No.
16/452,239
Granted
Apr 21, 2020
Kind
B2
Abstract

A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.

Claims (13)

1. A sealed dosage container consisting essentially of:

an aqueous solution of a hydroxycitrate salt and glycerol,

wherein the hydroxycitrate salt is a salt of a (−)-hydroxycitric acid selected from the group consisting of sodium, potassium, potassium-magnesium, magnesium hydroxycitrate, double salts based on the counter ions magnesium, potassium and sodium, triple-metal salts based on the counter ions magnesium, potassium and sodium, and combinations thereof, present in a therapeutically effective amount sufficient to suppress appetite of a human in need thereof;

wherein the liquid sealed dosage is prepared by a process consisting essentially:

mixing glycerol and purified water together, wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the purified water is present in an amount of about 3 to 1 parts by volume to create a glycerol and purified water solution; and

dissolving the hydroxycitrate salt in the glycerol and purified water solution to obtain an hydroxycitrate salt concentration ranging from about 1.1 to 1.7 molar dosage.

2. The sealed dosage container of claim 1 , wherein the hydroxycitrate salt is a stable hydroxycitrate salt.

3. The sealed dosage container of claim 1 , wherein the hydroxycitrate salt is a potassium-magnesium salt of (−)-hydroxycitric acid.

4. The sealed dosage container of claim 1 ,

wherein the hydroxycitrate salt is a sodium salt,

wherein the glycerol is completely dissolved in the water before the hydroxycitrate salt is dissolved therein, and

wherein the aqueous solution is substantially free of lactones of the hydroxycitrate salt.

5. The sealed dosage container of claim 1 , wherein the hydoxycitrate salt is present in the sealed container in amount of 3.0 g to 4.5 g ±20%, and the glycerol is present in the container in an amount in a range of from 1.0 g to 4.0 g ±20%.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2022
From: GLYKON TECHNOLOGIES GROUP, LLC
To: NUTRITION RESEARCH GROUP, LIMITED
Reel/Frame 058559/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2019
From: DOUGLASS, BRAD J.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 051013/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: CLOUATRE, DALLAS L.; CLOUATRE, DANIEL E.; DOUGLASS, BRAD J.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 051000/0517 →
Continuity (5)
Continuation 15975424 · May 9, 2018
Continuation 15701107 · Sep 11, 2017
Continuation 14614201 · Feb 4, 2015
Provisional Application 62081161 · Nov 18, 2014
Related Publication 20190314310A1 · Oct 17, 2019